Breast cancer
Conditions
Interventions
FES-PET and blood sampling for cell-free DNA analysis
Sponsors
Kobe City Medical Center General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: i) Twenty years old or older when informed consent is obtained ii) Have been diagnosed with estrogen receptor-positive breast cancer and planned new treatment or changing treatment regimen. iii) FDG PET has been or will be performed within 60 days before or after the FES PET to be performed in this study, and no new treatment will be initiated between these two scans iv) Have obtained consent for disclosure of FES PET results v) Oral and written consent has been obtained
Exclusion criteria
Exclusion criteria: i) In pregnant or with the possibility of pregnancy ii) Selective estrogen-receptor degrader or selective estrogen-receptor modulator are administered within 30 days of FES PET iii) Referring doctor decided inappropriate to join this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relation between the ratio of ESR1 genetic mutation and FES/FDG PET inconsistency | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Relation between FES-PET findings and the pathological result of estrogen receptor 2. Relation between clinical outcome and ESR1 genetic mutation and FES/FDG PET inconsistency | — |
Countries
Japan
Contacts
Public ContactTomohiko Yamane
Kobe City Medical Center General Hospital Molecular Imaging Research
Outcome results
None listed